Mark Dittmar

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

Mark Dittmar, Jae Seung Lee, Kanupriya Whig et al. · Cell Reports · 2021 · 245 citations · Full text

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2

D. Schultz, Robert M. Johnson, Kasirajan Ayyanathan et al. · Nature · 2022 · 192 citations · Full text

Pyrimidine Inhibitors, Medicine, Antiviral Drug Development +4

Pharmacological activation of STING blocks SARS-CoV-2 infection

Minghua Li, Max Ferretti, Baoling Ying et al. · Science Immunology · 2021 · 186 citations · Full text

Innate Immune Pathways, Innate Immune System, Immunology +16

SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms

Christine Vazquez, Sydnie Swanson, Seble G. Negatu et al. · PLoS ONE · 2021 · 119 citations · Full text

Distinct Mechanisms, Inflammatory Lung Disease, Lung Inflammation +18

Identification of antiviral roles for the exon–junction complex and nonsense-mediated decay in flaviviral infection

Minghua Li, Jeffrey R. Johnson, Billy Truong et al. · Nature Microbiology · 2019 · 88 citations · Full text

Molecular Virology, Pathogenesis, Flaviviral Infection +9